MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lacerda, A. E.
Right arrow Articles by Rampe, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacerda, A. E.
Right arrow Articles by Rampe, D.

0026-895X/97/020314-09$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:314-322 (1997).

Interactions of the Nonsedating Antihistamine Loratadine with a Kv1.5-Type Potassium Channel Cloned from Human Heart

Antonio E. Lacerda, Mary-Louise Roy, Eric W. Lewis, and David Rampe

The Rammelkamp Center, MetroHealth System, Cleveland, Ohio 44109 (A.E.L. and M.-L.R.), Nippon Hoechst Marion Roussel, Tokyo 107, Japan (E.W.L.), and Hoechst Marion Roussel, Inc., Cincinnati, Ohio 45215 (D.R.)

The use of nonsedating antihistamines may, on rare occasions, be associated with cardiac arrhythmias. This could be due to blockade of voltage-dependent K+ channels in the heart, leading to a prolongation in repolarization in the human myocardium. For this reason, we examined the effects of the nonsedating antihistamine loratadine on a rapidly activating delayed-rectifier K+ channel (Kv1.5) cloned from human heart and stably expressed in HEK 293 cells or mouse Ltk- cells. Using patch-clamp electrophysiology, we found that loratadine blocked Kv1.5 current measured from inside-out membrane patches at concentrations of >= 100 nM, resulting in an IC50 value of 808 nM at +50 mV. The drug enhanced the rate of Kv1.5 current decay, and block was enhanced at membrane potentials near threshold relative to higher potentials. Loratadine did not alter the kinetics of Kv1.5 current activation or deactivation. Unitary Kv1.5 currents were recorded in cell-attached patches. At the single-channel level, the main effect of loratadine was to reduce the mean probability of opening of Kv1.5. This effect of loratadine was achieved by a reduced number of openings in bursts and burst duration. Finally, loratadine (10 µM) failed to inhibit HERG K+ channel currents expressed in Xenopus laevis oocytes. It is concluded that loratadine is an effective blocker of Kv1.5 that interacts with an activated state or states of the channel. This interaction suggests a potential for loratadine to alter cardiac excitability in vivo.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. E. Kim, H. S. Ahn, B. H. Choi, H.-J. Jang, M.-J. Kim, D.-J. Rhie, S.-H. Yoon, Y.-H. Jo, M.-S. Kim, K.-W. Sung, et al.
Open Channel Block of A-Type, Kv4.3, and Delayed Rectifier K+ Channels, Kv1.3 and Kv3.1, by Sibutramine
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 753 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
B. H. Choi, J.-A. Park, K.-R. Kim, G.-I. Lee, Y.-T. Lee, H. Choe, S.-H. Ko, M.-H. Kim, Y.-H. Seo, and Y.-G. Kwak
Direct block of cloned hKv1.5 channel by cytochalasins, actin-disrupting agents
Am J Physiol Cell Physiol, August 1, 2005; 289(2): C425 - C436.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
A.E. Lacerda, J. Kramer, K.-Z. Shen, D. Thomas, and A.M. Brown
Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K23 - K30.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
I. Cavero and W. Crumb
Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K53 - K63.
[Abstract] [PDF]

Home page
 Pharmacol. Rev.Home page
C.-C. Shieh, M. Coghlan, J. P. Sullivan, and M. Gopalakrishnan
Potassium Channels: Molecular Defects, Diseases, and Therapeutic Opportunities
Pharmacol. Rev., December 1, 2000; 52(4): 557 - 594.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. J. Crumb Jr.
Loratadine Blockade of K+ Channels in Human Heart: Comparison with Terfenadine under Physiological Conditions
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 261 - 264.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
M. Taglialatela, A. Pannaccione, P. Castaldo, G. Giorgio, Z. Zhou, C. T. January, A. Genovese, G. Marone, and L. Annunziato
Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines
Mol. Pharmacol., July 1, 1998; 54(1): 113 - 121.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Cell Physiol.Home page
B. H. Choi, J.-S. Choi, D.-J. Rhie, S. H. Yoon, D. S. Min, Y.-H. Jo, M.-S. Kim, and S. J. Hahn
Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor
Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1461 - C1468.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics